BioCentury | Dec 3, 2020
Product Development

After Phase III miss, PharmaMar and Jazz may need new monotherapy trial to confirm cancer drug’s benefit

...to treat small cell lung cancer. Jazz Pharmaceuticals plc (NASDAQ:JAZZ), which has U.S. rights to Zepzelca lurbinectedin...
...$6.45 to $151 on Thursday. TARGETSPol II – RNA polymerase II Paul Bonanos Zepzelca, Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) Jazz...
BioCentury | Jun 17, 2020
Product Development

June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more

...a video game. Approval adds to Jazz’s cancer portfolio FDA granted accelerated approval to Zepzelca lurbinectedin...
...Interleukin-1 Pol II - RNA polymerase II BioCentury Staff teplizumab (MGA031, PRV-031) Ilaris, canakinumab (ACZ885) Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) avalglucosidase...
BioCentury | Feb 18, 2020
Regulation

Regulatory Roundup: PharmaMar-Jazz, BioCryst products under FDA review; plus EU approvals of Vyndaqel, Beovu; and more

...label to treat a form of amyloidosis. FDA granted Priority Review to an NDA for lurbinectedin...
...rights in the U.S. to lurbinectedin, to which the Spanish biopharma has sometimes referred as Zepsyre...
...TTR - Transthyretin VEGF - Vascular endothelial growth factor Paul Bonanos, Associate Editor Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) BCX7353 vadadustat...
BioCentury | Dec 19, 2019
Company News

PharmaMar deal adds late-stage asset to Jazz’s growing cancer pipeline

...Jazz’s deal to gain exclusive, U.S. rights to PharmaMar’s Zepsyre marks the company’s third cancer partnership...
...receive $200 million up front and up to $250 million upon FDA approval of Zepsyre lurbinectedin...
...Signal transducer and activator of transcription 3 Elizabeth S. Eaton, Staff Writer Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) Jazz...
BioCentury | Aug 19, 2019
Company News

Aug. 19 Company Quick Takes: PharmaMar gets bump on FDA timeline in SCLC; plus Shionogi, Vanda and Moderna

...dialogue with FDA, it will submit an NDA next quarter seeking accelerated approval of Zepsyre lurbinectedin...
...Zika. Paul Bonanos, Associate Editor and Mary Romeo, Assistant Editor cefiderocol (S-649266) Hetlioz, tasimelteon (VEC-162) MRNA-1893 Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) Moderna...
BioCentury | May 16, 2019
Clinical News

May 16 ASCO Quick Takes: Aduro ends MM trial; plus Puma, PharmaMar, Genocea, J&J

...p=0.2086) vs. Tykerb lapatinib plus capecitabine. PharmaMar reports 35.2% ORR for Zepsyre in SCLC Zepsyre lurbinectedin...
...Editor APRIL (BION-1301) GEN-009 JNJ-61186372 Nerlynx (Brand), PB272 (Compound #), HKI-272 (Compound #), Oral neratinib (Generic) Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) Aduro...
BioCentury | May 1, 2019
Company News

April 30 Company Quick Takes: Merck, G1, Pfizer, Amgen and more

...Pharma Group Ltd. (HKSE:2186) partnered with PharmaMar S.A. (Madrid:PHM) to develop and commercialize PharmaMar's Zepsyre lurbinectedin...
...ivacaftor (VX-770) Mavyret, Maviret, ABT-493/ABT-530, glecaprevir/pibrentasvir Skyrizi, risankizumab (ABBV-066, BI 655066) trilaciclib (G1T28, iv g1t28-1) Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) AbbVie...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Oral sulopenem Uncomplicated UTI Phase III data; submit NDA 2H19; YE19 PharmaMar S.A. (Madrid:PHM) Zepsyre lurbinectedin...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...S.A. (Madrid:PHM) / Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) / Specialised Therapeutics Australia Pty. Ltd. Zepsyre lurbinectedin...
BioCentury | Jan 26, 2018
Clinical News

PharmaMar's Zepsyre misses in Phase III for platinum-resistant ovarian cancer

...PharmaMar S.A. (Madrid:PHM) said Zepsyre lurbinectedin (PM01183, PM1183) missed the primary endpoint of improving progression-free survival...
...a Phase III protocol to evaluate Zepsyre plus doxorubicin as second-line treatment of endometrial cancer. Zepsyre...
...Pty. Ltd., Melbourne, Australia Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Product: Zepsyre lurbinectedin (PM01183, PM1183...
Items per page:
1 - 10 of 40